Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA Approves Canakinumab to Treat Gout Flares

  |  Issue: December 2023  |  

References

  1. Supplemental approval letter Ilaris (canikinumab). U.S. Food & Drug Administration. 2023 Aug 25.
  2. Highlights of prescribing information: Ilaris (canakinumab). U.S. Food & Drug Administration. 2009 Jun 17.
  3. Highlights of prescribing information: Ilaris (canakinumab). U.S. Food & Drug Administration. 2023 Aug.
  4. Gever J. What changed FDA’s mind about Ilaris for gout? Approval comes after previous rejections. Medpage Today. 2023 Sep 5.
  5. Supplemental approval letter: Ilaris (canakinumab). U.S. Food & Drug Administration. 2020 Jun 16.

Related Articles
    Mattew - Bilder und mehr / shutterstock.com

    Yao Syndrome: A Case Report & Clinical Review

    Case Presentation History of present illness A 66-year-old white woman presented with unexplained, recurrent episodes of high fever, abdominal pain, rash and arthralgias occurring over the previous three years. During typical episodes, the patient experienced flu-like symptoms, followed by fever, abdominal pain and non-bloody diarrhea without tenesmus. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEHer temperatures were 101–103ºF,…